Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients

AIDS

Volumn 25, Issue 18, 2011, Pages 2197-2208

  Soriano, Vincent ^a   Sherman, Kenneth E ^b   Rockstroh, Juergen ^c   Dieterich, Douglas ^d   Back, David ^e   Sulkowski, Mark ^f   Peters, Marion ^g  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

boceprevir; co infection; direct acting antivirals; drug resistance; hepatitis C; HIV; liver; telaprevir

Indexed keywords

ALISPORIVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; BOCEPREVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ERYTHROPOIETIN; ESCITALOPRAM; ESOMEPRAZOLE; ESTROGEN; FOSAMPRENAVIR PLUS RITONAVIR; INTERFERON LAMBDA; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHADONE; MIDAZOLAM; PEGINTERFERON ALPHA; PLACEBO; PROGESTERONE; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; TELAPREVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LIVER TRANSPLANTATION; MIXED INFECTION; NAUSEA; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PRURITUS; RETREATMENT; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; VOMITING;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 80855137985     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834bbb90     Document Type: Review

References (79)

1. Weber R, Sabin C, Friis-Møller N, Reiss P, El-Sadr W, Kirk O, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-1641. (Pubitemid 44232373)
2. Ruppik M, Ledergerber B, Rickenbach M, Furrer H, Battegay M, Cavassini M, et al. Changing patterns of causes of death: SCCS, 2005 to 2009 [abstract 789]. In: CROI 2011; 27 February to 2 March 2011; Boston, Massachusetts, USA.
3. Merwat S, Vierling J. HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury. Clin Liver Dis 2011; 15:131-152.
4. Peters M, Soriano V. HIV and the liver. In: Dooley J, Lok A, Burroughs A, Heathcote J, editors. Sherlock's diseases of the liver and biliary system. 12th ed. Oxford: Blackwell Publishing Ltd; 2011. pp. 438-451.
5. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089. (Pubitemid 46763278)
6. Rockstroh J, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88. (Pubitemid 351228130)
7. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liverrelated mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
8. Shafran S. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44:551-556. (Pubitemid 46594898)
9. Blanco F, Barreiro P, Ryan P, Vispo E, Martín-Carbonero L, Tuma P, et al. Risk factors for advanced liver fibrosis in HIVinfected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18:11-16.
10. Soriano V, Puoti M, Garcia-Gascó P, Rockstroh J, Benhamou Y, Barreiro P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1-13. (Pubitemid 350301936)
11. Nuñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52:1143-1155.
12. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670-676. (Pubitemid 47293847)
13. Dore G, Torriani F, Rodriguez-Torres M, Brau N, Sulkowski M, Sola R, et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007; 21:1555-1559. (Pubitemid 47075476)
14. Medrano J, Resino S, Vispo E, Madejon A, Labarga P, Tuma P, et al. HCV treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18:325-330.
15. Poveda E, Vispo E, Barreiro P, de Mendoza C, Labarga P, Fernandez-Montero JV, et al. Predicted challenges using direct acting antivirals in the current HIV-HCV coinfected population in Spain. Antivir Ther (in press).
16. Maida I, Núñez M, González-Lahoz J, Soriano V. Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation? AIDS Res Hum Retroviruses 2005; 21:599-601. (Pubitemid 41113646)
17. Tan-Tam C, Frassetto L, Stock P. Liver and kidney transplantation in HIV-infected patients. AIDS Rev 2009; 11:190-204.
18. Soriano V, Peters M, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 2009; 48:313-320.
19. Sherman K, Flamm S, Afdhal N, for the ILLUMINATE Team. Telaprevir combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid virological response: final results of phase 3 ILLUMINATE study [abstract LB-2]. In: 61th American Association for the Study of Liver Diseases (AASLD); 29 October to 2 November 2010; Boston, Massachusetts, USA.
20. Jacobson I, McHutchison J, Dusheiko G, di Bisceglie A, Reddy K, Bzowej N, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
21. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
22. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
23. McHutchison J, Manns M, Muir A, Terrault N, Jacobson I, Afdhal N, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-1303.
24. Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 h with ribavirin and peginterferon alfa-2a or 2b to patients with chronic hepatitis C. Gastroenterology 2011; 140:459-468.
25. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1HCV(SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-716.
26. Poordad F, McCone J, Bacon B, Bruno S, Manns M, Sulkowski M, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
27. Bacon B, Gordon S, Lawitz E, Marcellin P, Vierling J, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
28. Seden K, Back D, Shoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010; 65:1079-1085.
29. Jiménez-Nácher I, Alvarez E, Morello J, Rodriguez-Nóvoa S, de Andrés S, Soriano V. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol 2011; 7:457-477.
30. Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24:F23-F29.
31. Nattermann J, Vogel M, Nischalke H, Danta M, Mauss S, Stellbrink H, et al. Genetic variation in IL28B and treatmentinduced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011; 203:595-601.
32. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51:1158-1167.
33. Lange C, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54:887-893.
34. Ryan P, Berenguer J, Michelaud D, Miralles P, Bellón JM, Alvarez E, et al. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2009; 50:109-110.
35. Cacoub P, Carrat F, Bedossa P, Lambert J, Pénaranda G, Pol S, et al. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antivir Ther 2009; 14:839-845.
36. Sulkowski M, Dietrich D, Sherman K, Rockstroh J, Adda N, Mahnke L, et al. Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN-a2a and RBV in HIV/HCV co-infected patients [abstract 146LB]. In: 18th CROI; 2011; Boston, Massachusetts, USA.
37. Soriano V, Perelson A, Zoulim F. Why different dynamics of selection of drug resistance in HIV, hepatitis B and C viruses? J Antimicrob Chemother 2008; 62:1-4. (Pubitemid 351865869)
38. Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, Lazzarin A. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51:106-108.
39. Plaza Z, Soriano V, Bar-Magen T, González MM, Di Lello F, Macías J, et al. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV-HCV coinfected patients. J Antimicrob Chemother (in press).
40. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antivir Res 2010; 85:303-315.
41. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281. (Pubitemid 32120863)
42. Mauss S, Valenti W, De Pamphilis J, Duff F, Cupelli L, Passe S, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferonbased therapy. AIDS 2004; 38:F21-F25. (Pubitemid 39179625)
43. Garcia-Benayas T, Blanco F, Soriano V. Weight loss in HIVinfected patients. N Engl J Med 2002; 347:1287-1288.
44. Fleischer R, Boxwell D, Sherman K. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004; 38: e79-e80.
45. Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Mart?́n-Carbonero L, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-437. (Pubitemid 352016736)
46. Mira JA, López-Cortés L, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-1373.
47. Rodríguez-Nóvoa S, Morello J, González M, Vispo E, Barreiro P, González-Pardo G, et al. Increase in serum bilirubin in HIV/hepatitis C virus-coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin. AIDS 2008; 22:2535-2537.
48. Van Heeswijk R, Vandervoorde A, Boogaerts G, Vangeneugden T, de Paepe E, Polo R, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract 119]. In: 18th CROI; 2011; Boston, Massachusetts, USA.
49. Van Heeswijk R, Gysen V, Boogaerts G, de Paepe E, Vangeneugden T, De Becker K, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir. In: 48th ICAAC; 13-17 September 2008; San Francisco, California, USA. A-966.
50. Van Heeswijk R, Boogaerts G, de Paepe E, De Becker K, van Solingen-Ristea R, Garg V, et al. The pharmacokinetic interaction between escitalopram or esomeprazole and telaprevir [abstract 76]. In: 11th International Workshop on Clinical Pharmacology of HCV; 4-6 November 2010; Boston, Massachusetts, USA.
51. Van Heeswijk R, Van de Voorde A, Verboven P, Boogaerts G, de Paepe E, van Solingen-Ristea R, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir [abstract 1244]. In: EASL; 30 March to 3 April 2011; Berlin, Germany. J Hepatol 2011; 54 (Suppl):S491-S492.
52. Ghosal A, Yuan Y, Tong W, Su A-D, Gu C, Chowdhury S, et al. Characterisation of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011; 39:510-521.
53. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion and drug-drug interactions [abstract 118]. In: 18th CROI; 27 February to 2 March 2011; Boston, Massachusetts, USA.
54. Rouzier R, Larrey D, Gane E, Wiercinska-Drapalo A, Chang L, Zhang Y, et al. Activity of danoprevir plus low-dose ritonavir (DNV/R) in combination with peginterferon alfa-2A (40KD) plus ribavirin (PEGIFNa-2A/RBV) in previous null responders [abstract 62]. In: 46th EASL; 2011; Berlin, Germany.
55. Soriano V, Vispo E, Barreiro P. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. AIDS 2011; 25:1013-1014.
56. Neumann A, Lam N, Dahari H, Gretch D, Wiley T, Layden T, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998; 282:103-107. (Pubitemid 28471138)
57. Guedj J, Perelson A. Second-phase HCV RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011; 53:1801-1808.
58. Rong L, Dahari H, Ribeiro R, Perelson A. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30-32.
59. Torriani F, Ribeiro R, Gilbert T, Schrenk U, Clauson M, Pacheco D, Perelson A. Hepatitis C virus (HCV) and HIV dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188:1498-1507. (Pubitemid 37523935)
60. Sherman K, Shire N, Rouster S, Peters M, James Koziel M, Chung R, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128:313-327. (Pubitemid 40431085)
61. Dixit N, Layden-Almer J, Layden T, Perelson A. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-924. (Pubitemid 40037156)
62. Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 2007; 14:387-391. (Pubitemid 46744049)
63. Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25:1025-1033.
64. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138:447-462.
65. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55:192-206.
66. Kieffer T, Kwong A, Picchio G. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65:202-212.
67. Bartels D, Zhou Y, Zhang E, Marcial M, Byrn R, Pfeiffer T, et al. Natural prevalence of HCV variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198:800-807.
68. Kuntzen T, Timm J, Berical A, Lennon N, Berlin A, Young S, et al. Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-1778.
69. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49:1069-1082.
70. Sun S, Bae A, Qi X, Harris J, Wong K, Miller M, et al. Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naive HCV patient isolates. J Viral Hepat (in press).
71. Bae A, Sun S, Qi X, Chen X, Ku K, Worth A, et al. Susceptibility of treatment-naive HCV clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 2010; 54:5288-5297.
72. Treviño A, de Mendoza C, Parra P, Rodriguez C, Madejon A, Plaza Z, et al. Natural polymorphisms associated with resistance to new antivirals against hepatitis C virus (HCV) in newly diagnosed HIV/HCV-coinfected patients in Spain. Antivir Ther 2011; 16:413-416.
73. Trimoulet P, Belzunce C, Faure M, Wittkop L, Reigadas S, Dupon M, et al. HCV protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med 2011; 12:506-509.
74. Blackward J, Ma G, Limketkai B, Welge J, Dryer P, Martin C, et al. Variability of the polymerase gene (NS5B) in HCVinfected women. J Clin Microbiol 2010; 48:4256-4259.
75. Torriani F, Rodriguez-Torres M, Rockstroh J, Lissen E, Gonzalez J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. (Pubitemid 38988593)
76. Aronsohn A, Jensen D. Distributive justice and the arrival of direct acting antivirals: who should be first in line? Hepatology 2001; 53:1789-1791.
77. Miro JM, Castells L, Valdivieso A, Torre-Cisneros J, Abradelo M, Fernandez J, et al. Treatment with pegIFNRRBV of 67 HIVR patients with recurrent HCV infection after liver transplantation [abstract 964]. In: CROI 2011; 27 February to 2 March 2011; Boston, Massachusetts, USA.
78. Garg V, van Heeswiijk R, Eun-Lee J, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-27.
79. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int 2011; 4:62-67.